<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4A7FD67D-7A17-456A-B658-59679012F340"><gtr:id>4A7FD67D-7A17-456A-B658-59679012F340</gtr:id><gtr:firstName>Anna</gtr:firstName><gtr:surname>Roca</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190085849"><gtr:id>5BAF5076-B2BB-46B5-96E3-A426278E5E80</gtr:id><gtr:title>Trial assessing impact of vaccination with a pneumococcal conjugate vaccine on nasopharyngeal carriage of pneumococci</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190085849</gtr:grantReference><gtr:abstractText>Pneumonia is one of the most important causes of serious illness among children in The Gambia caused by a germ. There are roughly 90 different types of these pneumococcal bacteria and these can spread from person to person through close contact. It is likely that a new vaccine (Prevenar R) will soon be introduced into childhood immunization programme in The Gambia. This vaccine can work only on seven types but does not contain two forms of the germ that are important causes of invasive disease in The Gambia. In addition, there are concerns that the disease could re-emerge if children were infected with the other types of pneumococcal not covered in the original vaccine. We want to determine whether the introduction of this vaccine into a community will result in an increase in the carriage rate of these germs in the nose and throat without apparent disease and compare it to the germs in the nose and throat of children who did not receive this vaccine but a vaccine that prevent meningitis as a control. Swabs will be collected from the throats by a small stick with wool on the end one to three times a year. Some members of the household will contribute a small volume of blood and saliva before and after vaccination and subsequently at 3, 12 and 24 months after the completion of the first round of vaccination.</gtr:abstractText><gtr:technicalSummary>Streptococcus pneumoniae is responsible for many deaths in young children in developing countries. The development of pneumococcal polysaccharide/protein conjugate vaccines offers a possible way of preventing these infections and results from initial trials are encouraging. It is likely that Prevenar R, a seven-valent pneumococcal conjugate vaccine, will soon be introduced into childhood immunization programme in The Gambia. Pneumococci of serotypes 1 or 5 are important causes of invasive disease in The Gambia but are found infrequently in the nasopharynx and are not contained in Prevenar R. Could introduction of Prevenar R enhance their ability to establish themselves in the nasopharynx and subsequently to cause invasive disease? For these reasons it is essential to determine whether the introduction of Prevenar R into a community where type 1 and type 5 pneumococci are important causes of invasive disease will result in an increase in the nasopharyngeal carriage rate of these and other pneumococcal serotypes, not contained in this vaccine. In order to study the effects of maximum immune pressure of the kind that will be seen only several years after routine use of the vaccine we propose to study the effects of vaccination of a whole community as well as that of vaccinating just the infant population.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>8102540</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bill and Melinda Gates Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pneumococcal population dynamics</gtr:description><gtr:id>6851F546-9FC0-4339-8AAD-84A8D9BCA774</gtr:id><gtr:impact>Outputs not yet available</gtr:impact><gtr:outcomeId>545ca8d7236691.97444121-1</gtr:outcomeId><gtr:partnerContribution>All groups provide samples for a multi-site analysis</gtr:partnerContribution><gtr:piContribution>Provide samples and expertise to an international collaboration group</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Community activity</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>76A5DB5E-C7E7-453F-BCCB-495680BD1618</gtr:id><gtr:impact>A community activity was performed to inform all the study villages in rural The Gambia of the potential public health benefits of the study. Key people from the community was invited to help us to engage all the community participants. Progress of the study have been annually presented.

Very high community participation on the study.</gtr:impact><gtr:outcomeId>AA6714E5890</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Education activity on herd effect of pneumococcal vaccines</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>42BB50C2-48F9-4E11-A439-914F8184A027</gtr:id><gtr:impact>A publication which resulted from this project was used for the RC-UK to develop, with the help of Anna Roca, educational material for high schools on herd effect of pneumococcal vaccines and design of vaccine trials.</gtr:impact><gtr:outcomeId>56dd897f6704a9.72539913</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.ase.org.uk/home/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Unit seminar: Impact of PCV vaccination on pneumococcal carriage in The Gambia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B796B4D6-638C-4B83-9055-B51D5A215CDD</gtr:id><gtr:impact>100 peers attended the talk. Discussion on results and implications for the uptake of pneumococcal vaccines in The Gambia

NA</gtr:impact><gtr:outcomeId>T25aX1BgeLY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel award for the ISPPD7</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>BE904895-A2A7-448E-AA33-64FB2A7FC992</gtr:id><gtr:outcomeId>oWmVzeZsfiC0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Short and Long-term Impact Evaluation Framework on PCV Vaccines</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>F7C09AD6-25B3-467D-93B5-7C4B1C82B9D7</gtr:id><gtr:outcomeId>mjH5zb1CL63</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Nasopharyngeal aspirates, blood and saliva samples were collected as part of the study in the years 2006, 2007 and 2008. As part of an ancillary study proposed (that is using the same initial funding) new nasopharyngeal aspirates were collected during 2010.</gtr:description><gtr:id>E731890B-3C6C-4666-86A2-4BB5BF43253F</gtr:id><gtr:impact>Bacterial isolates resulting from the nasopharyngeal aspirates. For the last cross-sectional performed (2010) the laboratory analysis is ongoing. 
For the blood and saliva samples, that is also being generated</gtr:impact><gtr:outcomeId>502C73C67BC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biological samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Several study's datasets created as part of the trial. Most of the datasets are already cleaned and kept in the local server while others are in cleaning process</gtr:description><gtr:id>8306745B-E88E-4C5E-8E2B-AE75C3B1EFF2</gtr:id><gtr:impact>These datasets are being used for statistical analysis (in progress)</gtr:impact><gtr:outcomeId>B2390D235A4</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Datasets</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>073D7C86-3E5B-4614-BD50-7A35D69E5BFB</gtr:id><gtr:title>A mathematical model of serotype replacement in pneumococcal carriage following vaccination.</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Society, Interface</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/789a421d44fb12ab4f55d9e4e5efddd0"><gtr:id>789a421d44fb12ab4f55d9e4e5efddd0</gtr:id><gtr:otherNames>Bottomley C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-5662</gtr:issn><gtr:outcomeId>pm_13456_26_24132203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1AE1D6A-FC31-4386-B188-68270A866084</gtr:id><gtr:title>The impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study.</gtr:title><gtr:parentPublicationTitle>Emerging themes in epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/789a421d44fb12ab4f55d9e4e5efddd0"><gtr:id>789a421d44fb12ab4f55d9e4e5efddd0</gtr:id><gtr:otherNames>Bottomley C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1742-7622</gtr:issn><gtr:outcomeId>56cc7076dcda47.57744733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0FE7B5E-8BBA-4713-B7EB-D9B3BC654CE5</gtr:id><gtr:title>Effect of age and vaccination with a pneumococcal conjugate vaccine on the density of pneumococcal nasopharyngeal carriage.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_13456_26_22700830</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75FB958F-3F5E-4345-BECF-3670B89A4B87</gtr:id><gtr:title>Pneumococcal antibody concentrations of subjects in communities fully or partially vaccinated with a seven-valent pneumococcal conjugate vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbd9cb794d60ad6017c8b7d55cbd8f5d"><gtr:id>bbd9cb794d60ad6017c8b7d55cbd8f5d</gtr:id><gtr:otherNames>Ota MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13456_26_22916192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AE40B66-DAE2-47A2-9A9C-109C7A80C133</gtr:id><gtr:title>Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e45d4500cf0278521a4ff8036e4e3aa"><gtr:id>4e45d4500cf0278521a4ff8036e4e3aa</gtr:id><gtr:otherNames>Adegbola RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>54523ea9d94e00.46839456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77E216F1-761A-4FB2-B402-25E2CE85B1E3</gtr:id><gtr:title>Temporal changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine.</gtr:title><gtr:parentPublicationTitle>PeerJ</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb42bc3812ea8f42388bc715021a61de"><gtr:id>cb42bc3812ea8f42388bc715021a61de</gtr:id><gtr:otherNames>Ebruke C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8359</gtr:issn><gtr:outcomeId>56cc6f0b9890a1.77158445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>408B8ABA-776A-4A7B-99DE-B69173954844</gtr:id><gtr:title>High genetic diversity of Staphylococcus aureus strains colonising the nasopharynx of Gambian villagers before widespread use of pneumococcal conjugate vaccines.</gtr:title><gtr:parentPublicationTitle>BMC microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb42bc3812ea8f42388bc715021a61de"><gtr:id>cb42bc3812ea8f42388bc715021a61de</gtr:id><gtr:otherNames>Ebruke C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2180</gtr:issn><gtr:outcomeId>58ca73219cbc61.72267186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B520AC7B-AB17-4CA9-98C2-FC564D44BC5B</gtr:id><gtr:title>Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control.</gtr:title><gtr:parentPublicationTitle>BMC microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d8e3ac2b2e11f7ccb87472119bf4c46"><gtr:id>1d8e3ac2b2e11f7ccb87472119bf4c46</gtr:id><gtr:otherNames>Bojang E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2180</gtr:issn><gtr:outcomeId>5aa79f35075008.48356488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>460F4921-C478-4FE4-8D96-83C370EF4511</gtr:id><gtr:title>Nasopharyngeal carriage of pneumococci four years after community-wide vaccination with PCV-7 in The Gambia: long-term evaluation of a cluster randomized trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13456_26_24086259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F59248D-AE25-4BE4-AE00-A43C662E5311</gtr:id><gtr:title>Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia.</gtr:title><gtr:parentPublicationTitle>Bulletin of the World Health Organization</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db43f348aaf5d9c0f1ba4ee19da6796d"><gtr:id>db43f348aaf5d9c0f1ba4ee19da6796d</gtr:id><gtr:otherNames>Burr SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0042-9686</gtr:issn><gtr:outcomeId>545ca4054b2d16.78595706</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9772B94-737C-4D96-BDC9-E42DED16DD66</gtr:id><gtr:title>Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0361db51415d8d4cce9e2fb002a631ad"><gtr:id>0361db51415d8d4cce9e2fb002a631ad</gtr:id><gtr:otherNames>Roca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>aBumCaM9Hi1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E786F25-6C13-4F28-ADEF-23DD84970170</gtr:id><gtr:title>Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal carriage in newborns in rural Gambia: a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/647342215b81b4d4dcd4d8a5b67db65a"><gtr:id>647342215b81b4d4dcd4d8a5b67db65a</gtr:id><gtr:otherNames>Egere U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13456_26_23185303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFD6AFEC-F505-422B-9B5F-1B5B0C0D1EE1</gtr:id><gtr:title>Prevalence and risk factors for Staphylococcus aureus nasopharyngeal carriage during a PCV trial.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbc760156b511f261cdad66beb677fd5"><gtr:id>cbc760156b511f261cdad66beb677fd5</gtr:id><gtr:otherNames>Bojang A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>5aa79f34d3dfe2.84797334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>065A935C-ACA6-4A43-ADAE-87A7AF72EA14</gtr:id><gtr:title>Nasopharyngeal colonization of Gambian infants by Staphylococcus aureus and Streptococcus pneumoniae before the introduction of pneumococcal conjugate vaccines.</gtr:title><gtr:parentPublicationTitle>New microbes and new infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0d1f15d6ba9959164008d2b5e17ed3d"><gtr:id>b0d1f15d6ba9959164008d2b5e17ed3d</gtr:id><gtr:otherNames>Usuf E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2052-2975</gtr:issn><gtr:outcomeId>56d94b57ac3aa7.91471766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCE3BE59-35FD-4B4F-9386-B29E9936AEC7</gtr:id><gtr:title>Seasonality of Pneumococcal Nasopharyngeal Carriage in Rural Gambia Determined within the Context of a Cluster Randomized Pneumococcal Vaccine Trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbc760156b511f261cdad66beb677fd5"><gtr:id>cbc760156b511f261cdad66beb677fd5</gtr:id><gtr:otherNames>Bojang A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56cc6f0bc3eb60.53313555</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190085849</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>